[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559498":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":33,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":33,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":33,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":33,"overallStatus":43,"whyStopped":33,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","EXPERIMENTAL","38 STEMI patients undergoing PCI who will receive the standard of care for 4 weeks and will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants and anti-ischemic measures (high intensity statin, ACEI or aldosterone) as per latest guidelines recommendations.",[13],"Drug: The standard care for the management of myocardial infarction post PCI",{"label":15,"type":10,"description":16,"interventionNames":17},"Test group","38 STEMI patients undergoing PCI who will receive the standard of care in addition to L-Carnitine 5 g intravenous administered as slow Iv push over 2-3 minutes (L-Carnitine 1 gm \u002F 5 mL Injection®, MEPACO, Egypt) prior to PCI and then 2 g orally (Carnitol 500 mg®, Global Napi, Egypt) daily for 4 weeks after PCI",[18,13],"Drug: L-Carnitine",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","L-Carnitine","L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm \u002F 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)",[15],[26],"levocarnitine",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"The standard care for the management of myocardial infarction post PCI","include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.",[9,15],[32],"Guideline-directed medical therapy for STEMI",null,[35],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"Mohamed Hamdy Mohamedy","CONTACT","+201151189985","mohamed.hamdy.mh@outlook.com",[41],{"facility":42,"status":43,"city":44,"state":33,"zip":33,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Ain Shams University Hospitals","RECRUITING","Cairo","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.24967,30.06263,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":33,"phoneExt":33,"email":56},"Ayman Saleh, Professor","maymanmsaleh@yahoo.com",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Mohamed H. Mohamedy","Teaching assistant at clinical pharmacy department","100559498","phase-2-effect-of-l-carnitine-on-biomarkers-of-myocardial-reperfusion-injury-in-patients-with-stemi-100559498",false,"NCT06564909","Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* Female or male aged \\>18 and \\\u003C 75 years.\n* STEMI patients undergoing PCI.\n\nExclusion Criteria:\n\n* Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery.\n* A late presentation (\\>12 h), unsuccessful primary PCI (residual stenosis \\>50% in the culprit lesion after procedure),\n* Pretreatment with thrombolytic or glycoprotein IIb\u002FIIIa inhibitor therapy before primary PCI,\n* Concurrent Infectious or active inflammatory disease,\n* Severe liver or renal disease, (aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 3x ULN or Total bilirubin \\> 3 x ULN), (CrCl \\\u003C 60 ml\u002Fmin (based on the Cockroft-Gault equation)\n* Neoplasm, or hematological disorders\n* Pregnant or breast-feeding patients\n* Active participation in another clinical study\n* Patients taking antioxidant drugs.\n* History of or known allergy or intolerability to the study medications","ALL","18 Years","75 Years",{"count":72,"type":73},76,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker",[79,80],"Reperfusion Injury, Myocardial","Myocardial Infarction","2025-06-22",{"date":83,"type":84},"2025-06-26","ACTUAL",{"date":86,"type":84},"2025-06-01",{"date":88,"type":73},"2026-03",{"name":5,"class":6},1]